- Q1 2024 Aclaris Therapeutics Inc Earnings Call TranscriptMay 07, 2024$1.3 (-4.55%)Earnings
- Aclaris Therapeutics Inc to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results Call TranscriptNov 13, 2023
- Aclaris Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Aclaris Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 Aclaris Therapeutics Inc Earnings Call TranscriptMay 08, 2023$8.89Earnings
- Aclaris Therapeutics Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) TranscriptMar 30, 2023
- Aclaris Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Aclaris Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- Aclaris Therapeutics Inc R&D Day (Virtual) TranscriptDec 07, 2021
- Aclaris Therapeutics Inc ATI-1777 Clinical Data Call TranscriptJun 08, 2021
- Aclaris Therapeutics Inc Annual Shareholders Meeting TranscriptJun 03, 2021
- Aclaris Therapeutics, Inc. - Special Call TranscriptJan 19, 2021
- Aclaris Therapeutics, Inc. - Special Call TranscriptJun 17, 2020
- Aclaris Therapeutics Inc Annual Shareholders Meeting TranscriptJun 04, 2020
- Q4 2019 Aclaris Therapeutics Inc Earnings Call TranscriptFeb 25, 2020$1.31Earnings
- Q3 2019 Aclaris Therapeutics Inc Earnings Call TranscriptNov 07, 2019$1.17Earnings
- Aclaris Therapeutics, Inc. - Special Call TranscriptOct 24, 2019
- Aclaris Therapeutics, Inc. - Special Call TranscriptSep 27, 2019
- Q2 2019 Aclaris Therapeutics Inc Earnings Call TranscriptAug 08, 2019$2.12Earnings
- Aclaris Therapeutics, Inc. - Special Call TranscriptJul 30, 2019
- Aclaris Therapeutics, Inc. - Special Call TranscriptJun 26, 2019
- Aclaris Therapeutics Presents 6-Month Results From Androgenetic Alopecia Study TranscriptJun 17, 2019
- Q1 2019 Aclaris Therapeutics Inc Earnings Call TranscriptMay 08, 2019$6.41Earnings
- Q4 2018 Aclaris Therapeutics Inc Earnings Call TranscriptMar 18, 2019Earnings
Aclaris Therapeutics, Inc. - Special Call Transcript
Good day, ladies and gentlemen, and welcome to the Aclaris presents top line data from AA-201 Topical Phase II trial. (Operator Instructions) As a reminder, this call is being recorded.
I would now like to introduce your host for today's conference, Ms. Kamil Jackson. You may begin.
Thank you. I'm Kamil Ali-Jackson, Chief Legal Officer for Aclaris.
Please note that earlier today, Aclaris issued its press release announcing results from our AA-201 Topical Phase II clinical trial for our investigational drug ATI-502. For those of you who have not yet seen it, you will find the release posted in the Investors section of our website at www.aclaristx.com.
Joining me today for the call are Dr. Neal Walker, President and Chief Executive Officer; Dr. Stuart Shanler, our Chief Scientific Officer; and Dr. David Gordon, our Chief Medical
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investorsā 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)